Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02397928 : Safety and Efficacy of TTFields Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Pathological or histological evidence of mesothelioma

2. ? 18 years of age

3. Not candidate for curative treatment (surgery or radiotherapy)

4. At least 4 weeks since major surgery

5. At least one measurable or evaluable lesion according to modified RECIST Criteria

6. ECOG Performance Status of 0-1

7. Life expectancy of at least 3 months

8. Participants of childbearing age must use effective contraception as indicated by the

9. All subjects must sign written informed consent.

10. Able to operate the NovoTTF-100L System independently or with the help of a caregiver

Exclusion Criteria:

1. Patient candidate for surgery or radiotherapy with curative intent

2. Previous chemotherapy or radiation

3. Prior malignancy requiring anti-tumor treatment (apart from in-situ cervical cancer,
in situ breast cancer, non-melanomatous skin cancers, or any malignancy for which
treatment was received and there is no evidence of disease for at least 5 years) or
concurrent malignancy

4. Significant co-morbidities within 4 weeks prior to enrollment, resulting in the
following laboratory findings:

1. Significant liver function impairment:

- AST or ALT > 3 times the upper limit of normal

- Total bilirubin ? 1.5 times upper limit of normal

2. Significant renal impairment (serum creatinine > 1.7 mg/dL)

3. Coagulopathy (as evidenced by PT or APTT >1.5 times control in subjects not
undergoing anticoagulation)

4. Thrombocytopenia (platelet count < 100 x 10^3/?L)

5. Neutropenia (absolute neutrophil count < 1.5 x 10^3/?L)

6. Anemia (Hb < 10 g/dL)

7. Severe acute infection

5. Significant comorbidity which is expected to affect patient's prognosis or ability to
receive the combined therapy:

1. History of significant cardiovascular disease unless the disease is well

Significant cardiac disease includes second/third degree heart block;
significant ischemic heart disease; poorly controlled hypertension; congestive
heart failure of the New York Heart Association (NYHA) Class II or worse (slight
limitation of physical activity; comfortable at rest, but ordinary activity
results in fatigue, palpitation or dyspnea)

2. History of arrhythmia that is symptomatic or requires treatment. Patients with
atrial fibrillation or flutter controlled by medication are not excluded from
participation in the trial

3. Active infection or any serious underlying medical condition that would impair
the ability of the patient to receive protocol therapy

4. History of any psychiatric condition that might impair the patient's ability to
understand or comply with the requirements of the study or to provide consent

6. Untreated brain metastases. Asymptomatic, pretreated brain metastases not requiring
steroids are allowed

7. Implanted pacemaker, defibrillator or other electrical medical devices

8. Known allergies to medical adhesives or hydrogel

9. Pregnant or breast feeding (all patients of childbearing potential must use effective
contraception method during the entire period of the study based on the
recommendation of the investigator or a gynecologist)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557